ArticleClinical ophthalmology (Auckland, N.Z.)2026
Incidence and Clinical Course of Intraocular Inflammation Following Pharmacy-Compounded Intravitreal Aflibercept 8mg for Neovascular AMD: A Real-World Cohort Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the incidence and clinical course of intraocular inflammation (IOI) after intravitreal aflibercept 8 mg (Eylea 8 mg - E8) injection in patients with neovascular age-related macular degeneration (nAMD) in Poland. Patients and Methods: This retrospective study included 867 eyes of 867 patients (591 female, 276 male) with nAMD treated with E8 at the 10 Results: IOI occurred in 20 patients, corresponding to an incidence of 2.31% per eye/patient and 0.58% per injection. Symptoms appeared a mean of 3.3 ± 1.9 days after injection, with decreased visual acuity (BCVA dropped from 0.22 ± 0.10 to 0.58 ± 0.45 logMAR, p=0.0005). All cases were managed with topical corticosteroids, 16/20 additionally received sub-Tenon triamcinolone, and 6 required oral prednisolone; 1 patient required pars plana vitrectomy. Nineteen patients resolved on medical therapy alone, while one patient required surgical intervention (pars plana vitrectomy) to achieve resolution. No retinal vasculitis occurred, and central retinal thickness remained stable during follow-up. Conclusion: In this first Polish cohort study, the incidence of IOI after E8 injection (2.31% per eye/patient) was higher than reported in registration trials, though episodes were generally mild and self-limited, without long-term visual impact. These findings may help inform clinical monitoring for patients receiving E8 for nAMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.